Envestnet Asset Management
IRWD icon

Envestnet Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Envestnet Asset Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Buy
+35,531
New +$137K ﹤0.01% 4694
2025
Q2 		– Sell
-26,728
Closed -$39.3K – 4500
2025
Q1 		$39.3K Buy
26,728
+15,456
+137% +$36.8K ﹤0.01% 4306
2024
Q4 		$49.9K Buy
+11,272
New +$45.7K ﹤0.01% 4263
2024
Q3 		– Sell
-18,935
Closed -$123K – 4269
2024
Q2 		$123K Buy
18,935
+2,223
+13% +$15.7K ﹤0.01% 4026
2024
Q1 		$146K Buy
16,712
+5,885
+54% +$71.4K ﹤0.01% 4014
2023
Q4 		$124K Sell
10,827
-164
-1% -$1.62K ﹤0.01% 3921
2023
Q3 		$106K Sell
10,991
-233,928
-96% -$2.29M ﹤0.01% 3866
2023
Q2 		$2.61M Sell
244,919
-261,035
-52% -$2.81M ﹤0.01% 2113
2023
Q1 		$2.23M Buy
505,954
+281,820
+126% +$3.16M ﹤0.01% 2129
2022
Q4 		$2.78M Buy
224,134
+9,778
+5% +$111K ﹤0.01% 1957
2022
Q3 		$2.22M Sell
214,356
-3,458
-2% -$39.2K ﹤0.01% 2021
2022
Q2 		$2.51M Buy
217,814
+21,205
+11% +$250K ﹤0.01% 1960
2022
Q1 		$2.47M Buy
196,609
+42,606
+28% +$488K ﹤0.01% 2076
2021
Q4 		$1.8M Buy
154,003
+84,215
+121% +$1.03M ﹤0.01% 2248
2021
Q3 		$911K Buy
69,788
+15,210
+28% +$197K ﹤0.01% 2610
2021
Q2 		$702K Buy
54,578
+3,032
+6% +$34.7K ﹤0.01% 2761
2021
Q1 		$576K Sell
51,546
-173
-0.3% -$1.83K ﹤0.01% 2762
2020
Q4 		$589K Buy
51,719
+10,893
+27% +$119K ﹤0.01% 2575
2020
Q3 		$367K Sell
40,826
-56,850
-58% -$565K ﹤0.01% 2636
2020
Q2 		$1.01M Buy
97,676
+46,492
+91% +$476K ﹤0.01% 1968
2020
Q1 		$516K Sell
51,184
-33,204
-39% -$390K ﹤0.01% 2218
2019
Q4 		$1.12M Buy
+84,388
New +$930K ﹤0.01% 1952
2018
Q1 		– Sell
-1,077
Closed -$14K – 2896
2017
Q4 		$14K Hold
1,077
– – ﹤0.01% 2568
2017
Q3 		$14K Buy
1,077
+436
+68% +$6K ﹤0.01% 2543
2017
Q2 		$10K Buy
+641
New +$9.31K ﹤0.01% 2705
2014
Q4 		– Sell
-119
Closed -$1K – 2618
2014
Q3 		$1K Buy
+119
New +$1.36K ﹤0.01% 2612

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Envestnet Asset Management's IRWD Position: Q2 2026 in Review

Envestnet Asset Management opened a new position in Ironwood Pharmaceuticals (IRWD) in Q2 2026: 35,531 shares worth $150K. The stake represents ﹤0.01% of the portfolio and ranks #4694 among its holdings. This is a return to the name: Envestnet Asset Management previously reported a position in IRWD as recently as Q1 2025.

Envestnet Asset Management first reported a position in IRWD in Q3 2014 and has held it in 26 quarters since. The position peaked at $2.78M in Q4 2022. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Envestnet Asset Management held 35,531 shares of Ironwood Pharmaceuticals worth $150K as of Q2 2026.
  • Ironwood Pharmaceuticals was a new Envestnet Asset Management position in Q2 2026.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4694 holding.
  • Envestnet Asset Management first reported a position in Ironwood Pharmaceuticals in Q3 2014 and has held it in 26 quarters since.
  • Envestnet Asset Management's Ironwood Pharmaceuticals position peaked at $2.78M in Q4 2022.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.